Intercure Ltd. INCR

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
42/100
Developing

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

About Intercure Ltd.

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with Cannasoul R&D Ltd. for the research, … Full INCR analysis →

Key risks

  • Scale Without Profitability Despite scale, profitability lags peers (score 0.29), suggesting limited competitive advantage.
  • Liquidity Concerns Liquidity is concerning (score 0.29), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
33
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where INCR ranks in Drug Manufacturers - Specialty & Generic

Intercure Ltd. ranks #44 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 48%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
40 Tilray Brands, Inc. TLRY 45/100 Developing
41 Organigram Holdings Inc. OGI 45/100 Developing
42 Perrigo Company plc PRGO 43/100 Developing
43 Viatris Inc. VTRS 43/100 Developing
44 Intercure Ltd. INCR 42/100 Developing
45 TherapeuticsMD, Inc. TXMD 42/100 Developing
46 Aytu BioPharma, Inc. AYTU 42/100 Developing
47 Journey Medical Corporation DERM 41/100 Developing
48 Lifecore Biomedical, Inc. LFCR 40/100 Developing

See every Pharma / Mature Biotech company ranked by moat score →

How INCR scores on the Corporate Default defenses

Pricing Power

Score 33 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 61 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 45 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 43 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 50 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 24 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding INCR's moat

What is Intercure Ltd.'s moat score?

Intercure Ltd. (INCR) scores 42 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #44 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 48%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Cost Advantage (61/100) and its weakest is Scale & Market Position (24/100).

How does Intercure Ltd. compare with other Drug Manufacturers - Specialty & Generic companies?

Intercure Ltd. ranks #44 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Viatris Inc. (VTRS) at 43 just above it and TherapeuticsMD, Inc. (TXMD) at 42 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Intercure Ltd. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Intercure Ltd.?

The Corporate Default template measures 6 defenses, and INCR scores: Pricing Power (33), Cost Advantage (61), Customer Stickiness (45), Capital Efficiency (43), Resilience (50), Scale & Market Position (24). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000